Yvonne Mowery

Positions:

Butler Harris Assistant Professor in Radiation Oncology

Radiation Oncology
School of Medicine

Assistant Professor of Radiation Oncology

Radiation Oncology
School of Medicine

Member of the Duke Cancer Institute

Duke Cancer Institute
School of Medicine

Education:

M.D. 2012

Duke University

Ph.D. 2012

Duke University

Intern, Medicine

Duke University School of Medicine

Resident, Radiation Oncology

Duke University School of Medicine

Grants:

The Duke Preclinical Research Resources for Quantitative Imaging Biomarkers

Administered By
Radiology
Awarded By
National Institutes of Health
Role
Co Investigator
Start Date
End Date

Patient Reported Outcomes and Financial Toxicity in Head and Neck Cancer

Administered By
Radiation Oncology
Role
Principal Investigator
Start Date
End Date

SARC Spore - Bridge Funding

Administered By
Radiation Oncology
Role
Co Investigator
Start Date
End Date

Mechanisms that Regulate Sarcoma Response to Immune Checkpoint Inhibition of PD-1

Administered By
Radiation Oncology
Role
Investigator
Start Date
End Date

Dissecting the Interplay between Tumor Mutational Load and the Immune System in Response of Primary Sarcomas to Radiation Therapy

Administered By
Radiation Oncology
Awarded By
Conquer Cancer Foundation
Role
Principal Investigator
Start Date
End Date

Publications:

Practice Patterns for the Treatment of Uveal Melanoma with Iodine-125 Plaque Brachytherapy: Ocular Oncology Study Consortium Report 5

© 2019 © 2019 S. Karger AG, Basel. Copyright: All rights reserved. Background: Treatment planning for I-125 plaque therapy for uveal melanoma has advanced significantly since the Collaborative Ocular Melanoma Study trial, with more widely available image-guided planning and improved dosimetry. Objective: We evaluated real-world practice patterns for I-125 plaque brachytherapy in the United States by studying practice patterns at centers that comprise the Ocular Oncology Study Consortium (OOSC). Methods: The OOSC database and responses to a treatment practice survey were evaluated. The database contains treatment information from 9 institutions. Patients included in the database were treated between 2010 and 2014. The survey was conducted in 2018 and current treatment planning methods and prescriptions were queried. Results: Examination of the OOSC database revealed that average doses to critical structures were highly consistent, with the exception of one institution. Survey responses indicated that most centers followed published guidelines regarding dose and prescription point. Dose rate ranged from 51 to 118 cGy/h. As of 2018, most institutions use pre-loaded plaques and fundus photographs and/or computed tomography or magnetic resonance imaging in planning. Conclusions: While there were differences in dosimetric practices, overall agreement in plaque brachytherapy practices was high among OOSC institutions. Clinical margins and planning systems were similar among institutions, while prescription dose, dose rates, and dosimetry varied.
Authors
Binder, C; Mruthyunjaya, P; Schefler, AC; Seider, MI; Crilly, R; Hung, A; Meltsner, S; Mowery, Y; Kirsch, DG; Teh, BS; Jennelle, RLS; Studenski, MT; Liu, W; Lee, C; Hayman, JA; Kastner, B; Hadsell, M; Skalet, AH
MLA Citation
Binder, C., et al. “Practice Patterns for the Treatment of Uveal Melanoma with Iodine-125 Plaque Brachytherapy: Ocular Oncology Study Consortium Report 5.” Ocular Oncology and Pathology, Jan. 2019. Scopus, doi:10.1159/000504312.
URI
https://scholars.duke.edu/individual/pub1424208
Source
scopus
Published In
Ocular Oncology and Pathology
Published Date
DOI
10.1159/000504312

PET Radiotherapy Response Assessment Using Encoder-Decoder Convolutional Neural Network and Pre-treatment Information: A Feasibility of Oropharynx Cancer IMRT

Authors
Chang, Y; Liu, C; Lafata, K; Wang, C; Cui, Y; Ren, L; Mowery, YM; Brizel, DM; Yin, FF
MLA Citation
Chang, Y., et al. “PET Radiotherapy Response Assessment Using Encoder-Decoder Convolutional Neural Network and Pre-treatment Information: A Feasibility of Oropharynx Cancer IMRT.” International Journal of Radiation Oncology*Biology*Physics, vol. 105, no. 1, Elsevier BV, 2019, pp. E413–E413. Crossref, doi:10.1016/j.ijrobp.2019.06.1615.
URI
https://scholars.duke.edu/individual/pub1414956
Source
crossref
Published In
International Journal of Radiation Oncology, Biology, Physics
Volume
105
Published Date
Start Page
E413
End Page
E413
DOI
10.1016/j.ijrobp.2019.06.1615

Nomogram to Predict Survival Benefit of Postoperative Radiotherapy for Major Salivary Gland Cancers

Authors
Jacobs, CD; Kahmke, R; Rocke, DJ; Barak, I; Jung, SH; Suneja, G; Mowery, YM
MLA Citation
Jacobs, C. D., et al. “Nomogram to Predict Survival Benefit of Postoperative Radiotherapy for Major Salivary Gland Cancers.” International Journal of Radiation Oncology*Biology*Physics, vol. 105, no. 1, Elsevier BV, 2019, pp. S183–S183. Crossref, doi:10.1016/j.ijrobp.2019.06.227.
URI
https://scholars.duke.edu/individual/pub1415203
Source
crossref
Published In
International Journal of Radiation Oncology, Biology, Physics
Volume
105
Published Date
Start Page
S183
End Page
S183
DOI
10.1016/j.ijrobp.2019.06.227

Dose-Distribution-Driven PET Image-based Outcome Prediction (DDD-PIOP): A Framework Design for Oropharyngeal Cancer IMRT Application

Authors
Wang, C; Liu, C; Lafata, K; Chang, Y; Cui, Y; Li, X; Mowery, YM; Brizel, DM; Yin, FF
MLA Citation
Wang, C., et al. “Dose-Distribution-Driven PET Image-based Outcome Prediction (DDD-PIOP): A Framework Design for Oropharyngeal Cancer IMRT Application.” International Journal of Radiation Oncology*Biology*Physics, vol. 105, no. 1, Elsevier BV, 2019, pp. S81–82. Crossref, doi:10.1016/j.ijrobp.2019.06.546.
URI
https://scholars.duke.edu/individual/pub1415204
Source
crossref
Published In
International Journal of Radiation Oncology, Biology, Physics
Volume
105
Published Date
Start Page
S81
End Page
S82
DOI
10.1016/j.ijrobp.2019.06.546

Targeting cell surface GRP78 enhances pancreatic cancer radiosensitivity through YAP/TAZ protein signaling.

Ionizing radiation (IR) can promote migration and invasion of cancer cells, but the basis for this phenomenon has not been fully elucidated. IR increases expression of glucose-regulated protein 78kDa (GRP78) on the surface of cancer cells (CS-GRP78), and this up-regulation is associated with more aggressive behavior, radioresistance, and recurrence of cancer. Here, using various biochemical and immunological methods, including flow cytometry, cell proliferation and migration assays, Rho activation and quantitative RT-PCR assays, we investigated the mechanism by which CS-GRP78 contributes to radioresistance in pancreatic ductal adenocarcinoma (PDAC) cells. We found that activated α2-Macroglobulin (α2M*) a ligand of the CS-GRP78 receptor, induces formation of the AKT kinase (AKT)/DLC1 Rho-GTPase-activating protein (DLC1) complex and thereby increases Rho activation. Further, CS-GRP78 activated the transcriptional coactivators Yes-associated protein (YAP) and tafazzin (TAZ) in a Rho-dependent manner, promoting motility and invasiveness of PDAC cells. We observed that radiation-induced CS-GRP78 stimulates the nuclear accumulation of YAP/TAZ and increases YAP/TAZ target gene expressions. Remarkably, targeting CS-GRP78 with C38 monoclonal antibody (Mab) enhanced radiosensitivity and increased the efficacy of radiation therapy by curtailing PDAC cell motility and invasion. These findings reveal that CS-GRP78 acts upstream of YAP/TAZ signaling and promote migration and radiation-resistance in PDAC cells. We therefore conclude that, C38 Mab is a promising candidate for use in combination with radiation therapy to manage PDAC.
Authors
Gopal, U; Mowery, Y; Young, K; Pizzo, SV
MLA Citation
Gopal, Udhayakumar, et al. “Targeting cell surface GRP78 enhances pancreatic cancer radiosensitivity through YAP/TAZ protein signaling..” J Biol Chem, vol. 294, no. 38, Sept. 2019, pp. 13939–52. Pubmed, doi:10.1074/jbc.RA119.009091.
URI
https://scholars.duke.edu/individual/pub1402404
PMID
31358620
Source
pubmed
Published In
The Journal of Biological Chemistry
Volume
294
Published Date
Start Page
13939
End Page
13952
DOI
10.1074/jbc.RA119.009091

Research Areas:

Immunotherapy
Neck--Cancer--Radiotherapy
Radiation Oncology